Detalles de la búsqueda
1.
Combined Endometrial Ablation and Levonorgestrel Intrauterine System Use in Women With Dysmenorrhea and Heavy Menstrual Bleeding: Novel Approach for Challenging Cases.
J Minim Invasive Gynecol
; 22(7): 1203-7, 2015.
Artículo
en Inglés
| MEDLINE | ID: mdl-26122898
2.
The role of orlistat combined with lifestyle changes in the management of overweight and obese patients with polycystic ovary syndrome.
Clin Endocrinol (Oxf)
; 80(3): 432-8, 2014 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-23909452
3.
Uterine volume and endometrial thickness in the early follicular phase in patients with polycystic ovary syndrome.
Endocr Pract
; 20(6): 540-7, 2014 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-24325993
4.
Prevalence of metabolic syndrome in women with polycystic ovary syndrome.
Clin Endocrinol (Oxf)
; 78(4): 586-92, 2013 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-22888988
5.
Comparison of markers of insulin resistance and circulating androgens between women with polycystic ovary syndrome and women with metabolic syndrome.
Hum Reprod
; 28(3): 785-93, 2013 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-23315058
6.
Platelet-derived microparticles in overweight/obese women with the polycystic ovary syndrome.
Gynecol Endocrinol
; 29(3): 250-3, 2013 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-23216335
7.
Age- and body mass index-related differences in the prevalence of metabolic syndrome in women with polycystic ovary syndrome.
Gynecol Endocrinol
; 29(10): 926-30, 2013 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-23885694
8.
Insulin resistance and endocrine characteristics of the different phenotypes of polycystic ovary syndrome: a prospective study.
Hum Reprod
; 27(2): 541-9, 2012 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-22144419
9.
Oral contraceptives increase platelet microparticle levels in normal-weight women with polycystic ovary syndrome.
Hormones (Athens)
; 19(4): 565-571, 2020 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-32078734
10.
The influence of combined oral contraceptives containing drospirenone on hypothalamic-pituitary-adrenocortical axis activity and glucocorticoid receptor expression and function in women with polycystic ovary syndrome.
Hormones (Athens)
; 14(1): 109-17, 2015.
Artículo
en Inglés
| MEDLINE | ID: mdl-25402380
11.
Associations of menstrual cycle irregularities with age, obesity and phenotype in patients with polycystic ovary syndrome.
Hormones (Athens)
; 14(3): 431-7, 2015.
Artículo
en Inglés
| MEDLINE | ID: mdl-26188231
12.
Elevated serum androstenedione is associated with a more severe phenotype in women with polycystic ovary syndrome (PCOS).
Hormones (Athens)
; 13(2): 213-21, 2014.
Artículo
en Inglés
| MEDLINE | ID: mdl-24776621
13.
Non-alcoholic fatty liver disease in women with polycystic ovary syndrome: assessment of non-invasive indices predicting hepatic steatosis and fibrosis.
Hormones (Athens)
; 13(4): 519-31, 2014.
Artículo
en Inglés
| MEDLINE | ID: mdl-25402369
14.
Metabolic syndrome in patients with the polycystic ovary syndrome.
Expert Rev Endocrinol Metab
; 8(6): 559-568, 2013 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-30736140
15.
Infertility treatment in polycystic ovary syndrome: lifestyle interventions, medications and surgery.
Front Horm Res
; 40: 128-41, 2013.
Artículo
en Inglés
| MEDLINE | ID: mdl-24002410
16.
Lifestyle intervention and anti-obesity therapies in the polycystic ovary syndrome: impact on metabolism and fertility.
Endocrine
; 44(3): 583-90, 2013 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-23625194
17.
The guidelines issued by the European Society for Human Reproduction and Embryology and the American Society for Reproductive Medicine regarding the induction of ovulation with metformin in patients with the polycystic ovary syndrome potentially require reconsideration.
Hormones (Athens)
; 12(2): 192-200, 2013.
Artículo
en Inglés
| MEDLINE | ID: mdl-23933688
18.
The clinical significance and primary determinants of hirsutism in patients with polycystic ovary syndrome.
Eur J Endocrinol
; 168(6): 871-7, 2013 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-23557988
19.
Association between menstrual cycle irregularities and endocrine and metabolic characteristics of the polycystic ovary syndrome.
Eur J Endocrinol
; 168(2): 145-52, 2013 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-23109645
20.
Increased frequency of the anti-mullerian-inhibiting hormone receptor 2 (AMHR2) 482 A>G polymorphism in women with polycystic ovary syndrome: relationship to luteinizing hormone levels.
J Clin Endocrinol Metab
; 98(11): E1866-70, 2013 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-23969185